SOPHiA GENETICS SA
SOPH Healthcare Health Information Services
SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue grew 27.2%, EPS grew 9.88%, free cash flow grew 6.50% and total debt rose 1.12%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow SOPH
SOPHiA GENETICS SA (SOPH) Piotroski F-score
SOPHiA GENETICS SA's Piotroski F-score for fiscal 2025 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 3 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 2 | (1.00) |
| FY2024 | 3 | (1.00) |
| FY2023 | 4 | 1.00 |
| FY2022 | 3 | (1.00) |
| FY2021 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (49.63%) | (34.58%) | Fail | 0 |
| Positive operating cash flow | (35.89m) | (44.51m) | Fail | 0 |
| Rising return on assets | (49.63%) | (34.58%) | Fail | 0 |
| Cash flow above net income | 43.11m | 17.98m | Pass | 1 |
| Falling long-term leverage | 0.30 | 0.07 | Fail | 0 |
| Rising current ratio | 1.96 | 3.71 | Fail | 0 |
| No new shares issued | 67,540,000 | 66,062,000 | Fail | 0 |
| Rising gross margin | 67.40% | 67.42% | Fail | 0 |
| Rising asset turnover | 0.49 | 0.36 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| WEAV Weave Communications, Inc. compare | 6 |
| NRC National Research Corporation compare | 6 |
| HSTM HealthStream, Inc. compare | 6 |
| CTEV Claritev Corporation compare | 5 |
| PHR Phreesia, Inc. compare | 5 |
| EVH Evolent Health, Inc compare | 5 |
| SOPH SOPHiA GENETICS SA | 2 |
| MDRX Veradigm Inc. compare | 1 |
| CARL Carlsmed, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover